论文部分内容阅读
目的 观察华蟾素联合酚妥拉明治疗慢性乙型肝炎的临床疗效。方法 将血清病毒标志物阳性 (HBVM )伴肝功异常的慢性乙型肝炎患者 92例 ,随机分为治疗组和对照组。治疗组 48例 ,用华蟾素联合酚妥拉明 ,对照组 44例 ,只用华蟾素治疗 ,疗程均为 60天。结果 治疗组HBsAg阴转 2例 (4 .2 % ) ,HBeAg阴转 17例 (3 5 .4% ) ,HBV DNA阴转 2 1例 (4 3 .8% ) ,对照组HBsAg阴转 1例 (2 .3 % ) ,HBeAg阴转 15例 (3 4.1% ) ,HBV DNA阴转 19例 (4 3 .8% ) ,对肝功能的改善两组均有明显效果 ,但治疗组优于对照组 (P <0 .0 1)。结论 华蟾素抑制乙肝病毒复制 ,促进HBsAg、HBV DNA阴转 ,改善肝功能 ,联用酚妥拉明可提高疗效
Objective To observe the clinical efficacy of cinobufacini combined with phentolamine in the treatment of chronic hepatitis B. Methods 92 cases of chronic hepatitis B patients with positive serum HBV markers (HBVM) and liver dysfunction were randomly divided into treatment group and control group. Treatment group of 48 cases, with cinobufotalin combined with phentolamine, control group, 44 cases, only cinobufotalin treatment, treatment were 60 days. Results In the treatment group, 2 cases (4.2%) had HBsAg negative conversion, 17 cases (35.4%) HBeAg negative conversion, 21 cases HBV DNA negative conversion (43.8%), and 1 case HBsAg negative conversion (2.3%), 15 cases of HBeAg negative conversion (31.1%), and 19 cases of HBV DNA negative conversion (43.8%), both of which had significant effect on improving liver function, but the treatment group was better than the control group Group (P <0. 01). Conclusion Cinobufacini inhibits hepatitis B virus replication, promotes HBsAg, HBV DNA negative conversion and improves liver function. Combined use of phentolamine improves the curative effect